收藏切换
Construction and optimization of the multi-level medical security system for rare disease drug
收藏切换
Xinyang CHEN1, 2, Ye CHEN1, 2, Jinxi DING1, 2, *
World Clinical Drug | 2024, 45(11) : 1132 - 1140
Less
收藏切换
World Clinical Drug | 2024, 45(11): 1132-1140
• Topic •
Construction and optimization of the multi-level medical security system for rare disease drug
Full
Xinyang CHEN1, 2, Ye CHEN1, 2, Jinxi DING1, 2, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2024-11-10 doi: 10.13683/j.wph.2024.11.004
Outline
收藏切换
Objectives

To evaluate the current situation of improvement of the affordability of rare disease drugs in China, and to provide recommendations for the construction and optimization of the multi-level medical security system for rare disease.

Methods

The reimbursement policies of outpatient chronic and special diseases, major medical expenses insurance, City Customized Commercial Health Insurance and medical assistance in 333 cities in China were collected, and the affordability of 5 National Reimbursement Drug List (NRDL) rare disease drugs with annual cost of more than 100 000 yuan and 6 non-NRDL drugs with annual cost of more than 900 000 yuan were evaluated by World Health Organization/Health Action International standard survey method.

Results

For the 6 high-value non-NRDL drugs only covered by the city customized commercial medical insurance (CCCMI), the payment years for these treatments was higher than 10 years, and the affordability was extremely poor. For 5 NRDL rare disease drugs, the affordability was poor (1.53—3.97 years) only under outpatient chronic and special disease coverage. When the major medical expenses insurance was articulated, teriflunomide (0.81 year) and recombinant human coagulation factor Ⅷ (0.91 year) were affordable, and the payment years of the other three drugs have a certain decrease. Following secondary reimbursement through CCCMI and third reimbursement through medical assistance, human coagulation factor Ⅷ(0.64 year) and miglustat (0.84 year) were also affordable. And there was a significant difference in the number of payment years after the multi-level medical security system.

Conclusion

Multi-level medical security system can effectively improve the affordability of medication for patients with rare diseases. In this regard, it is recommended that non-NRDL rare disease drugs should be included in NRDL as soon as possible, and the link of various levels of reimbursement should be strengthened.

rare disease drug  /  multi-level medical security system  /  affordability
陈昕阳, 陈烨, 丁锦希. 罕见病用药多层次医疗保障体系的构建与优化. 世界临床药物, 2024 , 45 (11) : 1132 -1140 . DOI: 10.13683/j.wph.2024.11.004
Xinyang CHEN, Ye CHEN, Jinxi DING. Construction and optimization of the multi-level medical security system for rare disease drug[J]. World Clinical Drug, 2024 , 45 (11) : 1132 -1140 . DOI: 10.13683/j.wph.2024.11.004
Year 2024 volume 45 Issue 11
15
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.11.004
  • Receive Date:2024-08-02
  • Online Date:2026-11-17
  • Published:2024-11-10
Article Data
Affiliations
History
  • Received:2024-08-02
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.11.004
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT